Quince Therapeutics is a biotechnology company focusing on developing therapies and treatments for degenerative diseases, such as Alzheimer's. Quince Therapeutics was incorporated in 2012 and is headquartered in South San Francisco, California.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Quince Therapeutics news
20.05.2022
Cortexyme has completed its merger with Novosteo, a biopharmaceutical company that develops drugs for rare skeletal diseases and bone cancer. Novosteo shareholders received 15.5% of the combined company, which will change its name to Quince Therapeutics in the coming months. Cortexyme also granted the transferred employees from Novosteo stock options of 3,74...
Source: 
ir.cortexyme.com
ir.cortexyme.com
10.05.2022
Cortexyme is merging with Novosteo, a biotechnology company that develops drugs to treat rare bone diseases and bone cancer. As a result, Novosteo shareholders will own 15.5% of the merged company, which will be named Quince Therapeutics and will be traded under the ticker symbol QNCX. The merger is expected to be completed within 30 days.
Source: ir.cortexyme.com
ir.cortexyme.com
09.08.2021
Cortexyme's GAAP loss for 6M 2021 was $44.84 million, up 28.9% from $34.788 million in the prior year.
Source: ir.cortexyme.com
ir.cortexyme.com
13.11.2020
Cortexyme's loss under GAAP for 9 months of 2020 was $56.294 million, up 2.3 times from $24.601 million the previous year.
Source: ir.cortexyme.com
ir.cortexyme.com
General information
| Company name | Quince Therapeutics |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 269 East Grand Avenue South San Francisco, CA 94080 United States |
| Mailing address | 269 East Grand Avenue South San Francisco, CA 94080 United States |
| Website | ir.quincetx.com |
| Information disclosure | www.sec.gov |
English (US) 